Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Exp Hematol Oncol ; 11(1): 86, 2022 Nov 04.
Artigo em Inglês | MEDLINE | ID: mdl-36333762

RESUMO

Acute lymphoblastic leukemia is the most common childhood malignancy. One of the drugs used in the treatment is Asparaginase, and monitoring of its activity levels enables better outcomes. Since 2018, our laboratory has been working to establish a regular analysis of activity. This implementation allowed to qualify care by detecting silent inactivation and also establishing desensitization as a safe way to overcome the lack of Erwinia. We were able to monitor children aged 0 to 18 years who were being treated with PEG-ASNase. The activity was assessed on days 7 (90 samples) and 14 (52 samples) after ASNase infusions. 142 samples were analyzed. 95.7% reached an adequate activity level (≥ 0.1 IU/mL). Patients treated with ASNase can develop allergic reactions. With the activity monitoring, is possible to circumvent situations like these and implement desensitization protocols for patients who had clinical hypersensitivity without inactivation. Desensitization induces temporary unresponsiveness to drug antigens, allowing the patients to proceed with the prescribed chemotherapy. We have received samples from four patients being treated with different desensitization protocols. Patients tolerated the protocols well. Only one had a grade 2 reaction during the infusion and activity < 0.1 IU/mL, which resulted in the switch to Erwinia. The dose adaptation is a possible and more recent use of ASNase monitoring and we were able to confirm the feasibility of PEG-ASNase desensitization protocols.

2.
Br J Haematol ; 194(1): 168-173, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-33993488

RESUMO

Our group recently showed that the (ASNase) formulation available in Brazil from 2017 to 2018 when used at the same dose and frequency as the formulation provided previously did not reach the activity considered therapeutic. Based on these, our goal was to assess the impact of these facts on the prognosis of children with ALL at different oncology centers. A multicentre retrospective observational study followed by a prospective follow-up. Patients aged >1 and <18 years in first-line treatment followed up at 10 referral centres, between 2014 and 2018 who received the formulation Leuginase® were identified (Group B). For each patient, the centre registered 2 patients who received ASNase in the presentation of Aginasa® exclusively (Group A). Data collection was registered using (Redcap® ). A total of 419 patients were included; 282 in Group A and 137 in B. Group A had a 3-year OS and EFS of 91·8% and 84·8% respectively, while Group B had a 3-year OS of 83·8% (P = 0·003) and EFS of 76·1% (P = 0·008). There was an impact on 3-year OS and EFS of children who received a formulation. This result highlights the importance of evaluating ASNase and monitoring its activity.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Asparaginase/farmacologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Adolescente , Asparaginase/administração & dosagem , Brasil/epidemiologia , Criança , Pré-Escolar , Composição de Medicamentos , Feminino , Seguimentos , Humanos , Lactente , Estimativa de Kaplan-Meier , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/mortalidade , Intervalo Livre de Progressão , Estudos Prospectivos , Estudos Retrospectivos
3.
J. pediatr. (Rio J.) ; 97(2): 204-210, Mar.-Apr. 2021. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1287020

RESUMO

Abstract Objective: This study aims to describe the epidemiological characteristics and survival rates of children with acute myeloid leukemia treated in hospitals in southern Brazil and compare them with international data. Methods: A multicenter cohort study was conducted with retrospective data collection of all new patients with acute myeloid leukemia under 18 treated at five referral centers in pediatric hematology-oncology in southern Brazil between January 2005 and December 2015. Results: Of the 149 patients with acute myeloid leukemia, 63.0% (n = 94) were male. The median age at diagnosis was 10.5 years (range 0-18 years) and 40.3% (n = 60) had a white blood cell count below 50,000/mm2. The most common Franco-American-British (FAB) subtype was M3 (n = 43, 28.9%). Nine (6.0%) patients had central nervous system disease. In M3 patients, overall survival (OS) was 69.2% and 3-year event-free survival was 67.7%; in non-M3 patients, these rates were 45.3% and 36.7%, respectively. In non-M3 patients, OS was significantly different between transplanted (61.8%) and non-transplanted (38.2%) patients (p = 0.031). Conclusions: These results show a higher prevalence of the Franco-American-British M3 subtype than that reported in the international literature, as well as a decreased OS compared with that of developed countries. Further multicenter Brazilian studies with a larger sample size are encouraged to better understand the characteristics of acute myeloid leukemia, and to improve the treatment and prognosis in this population.


Assuntos
Humanos , Masculino , Recém-Nascido , Lactente , Pré-Escolar , Criança , Adolescente , Leucemia Mieloide Aguda/epidemiologia , Prognóstico , Brasil/epidemiologia , Estudos Retrospectivos , Estudos de Coortes
4.
J Pediatr (Rio J) ; 97(2): 204-210, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-32325011

RESUMO

OBJECTIVE: This study aims to describe the epidemiological characteristics and survival rates of children with acute myeloid leukemia treated in hospitals in southern Brazil and compare them with international data. METHODS: A multicenter cohort study was conducted with retrospective data collection of all new patients with acute myeloid leukemia under 18 treated at five referral centers in pediatric hematology-oncology in southern Brazil between January 2005 and December 2015. RESULTS: Of the 149 patients with acute myeloid leukemia, 63.0% (n=94) were male. The median age at diagnosis was 10.5 years (range 0-18 years) and 40.3% (n=60) had a white blood cell count below 50,000/mm2. The most common Franco-American-British (FAB) subtype was M3 (n=43, 28.9%). Nine (6.0%) patients had central nervous system disease. In M3 patients, overall survival (OS) was 69.2% and 3-year event-free survival was 67.7%; in non-M3 patients, these rates were 45.3% and 36.7%, respectively. In non-M3 patients, OS was significantly different between transplanted (61.8%) and non-transplanted (38.2%) patients (p=0.031). CONCLUSIONS: These results show a higher prevalence of the Franco-American-British M3 subtype than that reported in the international literature, as well as a decreased OS compared with that of developed countries. Further multicenter Brazilian studies with a larger sample size are encouraged to better understand the characteristics of acute myeloid leukemia, and to improve the treatment and prognosis in this population.


Assuntos
Leucemia Mieloide Aguda , Adolescente , Brasil/epidemiologia , Criança , Pré-Escolar , Estudos de Coortes , Humanos , Lactente , Recém-Nascido , Leucemia Mieloide Aguda/epidemiologia , Masculino , Prognóstico , Estudos Retrospectivos
5.
Clin. biomed. res ; 41(3): 192-198, 20210000. graf
Artigo em Inglês | LILACS | ID: biblio-1344765

RESUMO

Introduction: Treatment of childhood acute lymphoblastic leukemia (ALL) is based on risk stratification. This study aimed to assess the agreement between risk group classifications in the different childhood ALL treatment protocols used in a referral hospital in southern Brazil. Methods: We retrospectively reviewed the medical records of patients aged 1 to 18 years with B-cell ALL treated at a hospital from January 2013 to April 2017. Agreement between risk classifications was assessed by the kappa coefficient. Results: Seventy-five patients were analyzed. There was poor agreement between risk stratification by GBTLI 2009 and BFM 95 protocols (kappa = 0.22; p = 0.003) and by GBTLI 2009 and IC-BFM 2002 protocols (kappa = 0.24; p = 0.002). Risk group distribution was 13.3% for low risk, 32.0% for intermediate risk, and 54.7% for high risk based on stratification by the GBTLI 2009 protocol, and 28.0% for low risk, 42.7% for intermediate risk, and 29.3% for high risk based on stratification by the IC-BFM 2002 protocol. Overall survival was 68.6%. Conclusion: This study provides numerous points to ponder about the treatment of leukemia in Brazil. The percentage of patients classified as high risk in our sample was higher than that reported in the international literature. This difference, however, had no impact on overall survival, which was shorter than that reported in the international literature. (AU)


Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Adolescente , Leucemia-Linfoma Linfoblástico de Células Precursoras B/mortalidade , Protocolos de Quimioterapia Combinada Antineoplásica , Fatores de Risco , Sobreviventes de Câncer
6.
Hematol., Transfus. Cell Ther. (Impr.) ; 42(4): 348-355, Oct.-Dec. 2020. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1142973

RESUMO

ABSTRACT Background: The minimal residual disease (MRD) is the most important prognostic factor for acute lymphoblastic leukemia (ALL) in children. This study aimed to investigate the influence of detecting the MRD by the multiparametric flow cytometry (MFC) at day 15 (D15) of the induction on the analysis of the risk group classifications of the different childhood ALL treatment protocols used in a referral hospital in southern Brazil. Method: We retrospectively reviewed the medical records of patients with B-cell ALL, aged 1 to 18 years, treated at a hospital from January 2013 to April 2017. Main results: Seventy-five patients were analyzed. Regarding the MRD by the MFC at D15, the analyses showed statistical significance when the MRD was grouped into three categories, < 0.1%, 0.1-10%, and > 10%, with the following distribution: 30.7%, 52.0%, and 17.3%, respectively. There was a significant association between D15 MRD-MFC < 0.1% and the likelihood of dying or relapsing and between D15 MRD-MFC > 10% and the likelihood of dying or relapsing. The cumulative hazard ratio for the relapse of patients with D15 MRD-MFC < 0.1%, 0.1-10%, and > 10% was 19.2%, 59.8%, and 80.1%, respectively. Conclusion: Our analysis suggests D15 MRD-MFC < 0.1% as a cut-off point for patients with more favorable outcomes and that the MRD at D15 in risk classifications is particularly useful for the stratification of patients with a more favorable prognosis.


Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Adolescente , Prognóstico , Encaminhamento e Consulta , Leucemia Aguda Bifenotípica/terapia , Fatores de Risco , Neoplasia Residual , Leucemia-Linfoma Linfoblástico de Células Precursoras
7.
Hematol Transfus Cell Ther ; 42(4): 348-355, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31924484

RESUMO

BACKGROUND: The minimal residual disease (MRD) is the most important prognostic factor for acute lymphoblastic leukemia (ALL) in children. This study aimed to investigate the influence of detecting the MRD by the multiparametric flow cytometry (MFC) at day 15 (D15) of the induction on the analysis of the risk group classifications of the different childhood ALL treatment protocols used in a referral hospital in southern Brazil. METHOD: We retrospectively reviewed the medical records of patients with B-cell ALL, aged 1 to 18 years, treated at a hospital from January 2013 to April 2017. MAIN RESULTS: Seventy-five patients were analyzed. Regarding the MRD by the MFC at D15, the analyses showed statistical significance when the MRD was grouped into three categories, < 0.1%, 0.1-10%, and > 10%, with the following distribution: 30.7%, 52.0%, and 17.3%, respectively. There was a significant association between D15 MRD-MFC < 0.1% and the likelihood of dying or relapsing and between D15 MRD-MFC > 10% and the likelihood of dying or relapsing. The cumulative hazard ratio for the relapse of patients with D15 MRD-MFC < 0.1%, 0.1-10%, and > 10% was 19.2%, 59.8%, and 80.1%, respectively. CONCLUSION: Our analysis suggests D15 MRD-MFC < 0.1% as a cut-off point for patients with more favorable outcomes and that the MRD at D15 in risk classifications is particularly useful for the stratification of patients with a more favorable prognosis.

8.
Rev. AMRIGS ; 54(2): 169-173, abr.-jun. 2010.
Artigo em Português | LILACS | ID: lil-685603

RESUMO

Introdução: As neoplasias malignas da tireoide não são comuns na faixa etária pediátrica. O objetivo deste trabalho foi realizar um levantamento epidemiológico e clínico dos casos de câncer de tireoide (CT) atendidos no Hospital Universitário de Santa Maria (HUSM) entre 1993 e 2008, com descrição do diagnóstico e da terapêutica, acompanhado de uma revisão de literatura dessa patologia. Métodos: Estudo de demanda retrospectivo a partir do registro do Serviço de Patologia do Hospital Universitário de Santa Maria, RS (HUSM), no período de 1/1/1993 a 31/12/2008. Resultados: Nos 15 anos avaliados, foram encontrados 10 pacientes com diagnóstico de CT. Este estudo de casos inclui sete dos 10 pacientes; os demais foram excluídos devido à insuficiência de dados nos prontuários. O sexo feminino foi o mais acometido. Seis dos sete pacientes foram submetidos à tireoidectomia total com esvaziamento ganglionar. O tipo histológico predominante foi o carcinoma papilífero e o tamanho médio dos tumores foi de 2 cm. As metástases linfonodais foram encontradas em seis casos no momento do diagnóstico e o número médio de linfonodos acometidos foi quatro. Conclusão: Os resultados encontrados são consistentes com os achados epidemiológicos e clínicos encontrados na literatura para esta faixa etária. Destaca-se a importância do seguimento de um protocolo de manejo do CT dentro de um hospital universitário


Introduction: Malignant neoplasms of the thyroid are not common in pediatric patients. The aim of this study was to carry out an epidemiological and clinical survey of the cases of thyroid cancer (TC) treated at the University Hospital of Santa Maria (HUSM) between 1993 and 2008, with a description of diagnoses and treatment, together with a literature review of this disorder. Methods: A retrospective, demand study based on the registry of the Department of Pathology, University Hospital of Santa Maria-RS (HUSM) from 1/1/1993 to 31/12/2008. Results: Over the past 15 years, there were 10 patients diagnosed with TC. This case study includes seven of the 10 patients, the others were excluded because of insufficient data in the charts. Females were more affected. Six of seven patients underwent total thyroidectomy with lymph node dissection. The predominant histological type was papillary carcinoma and the average size of tumors was 2 cm. Lymph node metastases were found in six cases at diagnosis and the mean number of affected lymph nodes was four. Conclusion: The results are consistent with epidemiological and clinical findings in the literature for this age group. The study highlights the importance of following a management protocol of CT within a university hospital


Assuntos
Criança , Adolescente , Carcinoma Papilar/diagnóstico , Carcinoma Papilar/epidemiologia , Carcinoma Papilar/terapia , Metástase Neoplásica/diagnóstico , Neoplasias da Glândula Tireoide/diagnóstico , Neoplasias da Glândula Tireoide/epidemiologia , Neoplasias da Glândula Tireoide/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...